An announcement from Aurinia Pharmaceuticals ( (AUPH) ) is now available.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aurinia Pharmaceuticals reported significant financial growth in Q3 2024, with net product revenue up by 36% year-over-year, driven by increased market penetration of LUPKYNIS. The company is undergoing strategic restructuring to focus on continued LUPKYNIS growth and AUR200 development, expecting annualized savings of over $40 million post-restructuring. With strong cash flow and revenue guidance between $210-$220 million for 2024, Aurinia aims to enhance operational efficiency and accelerate key pipeline products.
See more insights into AUPH stock on TipRanks’ Stock Analysis page.